FIGURE 2.

ARHGAP30 inhibited cervical cancer growth in vitro and in vivo. A, Upper panel: ARHGAP30 mRNA level in various cervical cancer cell lines. Lower panel: ARHGAP30 protein level in various cervical cancer cell lines with ACTB detected as the internal control. B, Validation of ARHGAP30 overexpression in cervical cancer cell lines using rt‐PCR and Western blot analysis. Flag antibody was detected for overexpression of ARHGAP30. C, Analysis of cervical cancer cell proliferation in vitro. Results are shown as the means ± standard deviation of the OD 450 value. D, Anchorage‐independent colony formation analysis. Statistical analysis is shown in the lower panel. E, Subcutaneous tumor growth in mice inoculated with Hela‐OV or Hela‐Vector cells. Each group of mice was randomly divided into two groups (n = 5 per group). Upper, Photos of tumors; middle, growth curve of tumors; lower, statistical analysis of tumor weight growth over 5 weeks. Data shown are the mean ± standard deviation. P values were calculated by t test. F, Representative images for Transwell migration assays and statistical analysis (lower panel). G, Apoptosis analysis of cells with or without ARHGAP30 overexpression. PI, propidium iodide. Statistical analysis is show in the right panel. *P < .05; **P < .01; ***P < .001